Palynziq market forecast points to faster growth in rare disease care

The Business Research Company says the global Palynziq market is set to grow through 2035 as PKU diagnosis improves, rare disease programs expand and reimbursement gets better. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Palynziq sits in a niche but growing rare-disease drug category tied to phenylketonuria, or PKU, a disorder that can cause neurological damage if phenylalanine levels stay high. - The market outlook signals more demand for enzyme substitution therapies as diagnosis improves and lifelong PKU management becomes more common. - Better access to screening and specialty care could broaden treatment reach in both established and emerging markets.

What happened: - The Business Research Company published its Palynziq Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Palynziq market has grown on better PKU detection, clinical results from enzyme substitution therapies, more rare disease programs, greater awareness among adult PKU patients, and more metabolic specialty clinics. - The report forecasts further growth from higher investment in rare disease drug development, wider newborn screening, broader lifelong PKU management, stronger orphan-drug reimbursement, and enzyme engineering advances. - Palynziq is the commercial name for pegvaliase-pqpz, a biologic medication used to treat PKU. - The drug supplies an enzyme that breaks down phenylalanine in the bloodstream and helps lower levels of the amino acid.

The details: - PKU is a rare inherited disorder in which the body cannot properly metabolize phenylalanine, an amino acid found in food. - The report says rising awareness of genetic disorders is a major driver of Palynziq demand worldwide. - That awareness is linked to broader access to genetic testing, advanced genomic sequencing, lower-cost home DNA kits, global early-diagnosis initiatives, and more genetic education in healthcare systems. - In July 2025, the Adult Polyglucosan Body Disease Research Foundation updated the global prevalence of GBE1-related disorders to 1 in 236,000 from 1 in 325,000 in 2022. - The study estimated about 34,000 people worldwide could be affected, pointing to better detection and data collection on rare conditions. - The report says North America held the largest Palynziq market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period. - The market report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future-trend analysis.

Between the lines: - The report is framing Palynziq as a proxy for broader momentum in rare-disease diagnosis and treatment. - The biggest growth signal is not just drug demand, but the systems around it: screening, reimbursement, specialty clinics and clinician awareness. - North America’s lead suggests the market still depends on mature healthcare infrastructure, while Asia-Pacific growth points to room for expansion as access improves.

What's next: - The market outlook points to continued demand if newborn screening expands and rare-disease programs keep scaling. - More reimbursement support for orphan drugs could make treatment easier to access for adult PKU patients. - The report’s forecast period runs through 2035, giving investors and drug makers a long runway to track adoption trends. - For more information, see the full report and a free sample of the report.